JP2020529996A - 肥大型心筋症の治療で使用するためのマバカムテン - Google Patents

肥大型心筋症の治療で使用するためのマバカムテン Download PDF

Info

Publication number
JP2020529996A
JP2020529996A JP2020505487A JP2020505487A JP2020529996A JP 2020529996 A JP2020529996 A JP 2020529996A JP 2020505487 A JP2020505487 A JP 2020505487A JP 2020505487 A JP2020505487 A JP 2020505487A JP 2020529996 A JP2020529996 A JP 2020529996A
Authority
JP
Japan
Prior art keywords
compound
individual
daily dose
plasma concentration
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020505487A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020529996A5 (enExample
Inventor
マーク・ジェイ・セミグラン
ジューン・エイチ・リー
ジョセフ・ランビン
エリック・グリーン
マーク・エヴァンチック
Original Assignee
マイオカーディア，インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マイオカーディア，インク filed Critical マイオカーディア，インク
Publication of JP2020529996A publication Critical patent/JP2020529996A/ja
Publication of JP2020529996A5 publication Critical patent/JP2020529996A5/ja
Priority to JP2023014110A priority Critical patent/JP2023065372A/ja
Priority to JP2024192836A priority patent/JP2025020292A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2020505487A 2017-08-04 2018-08-03 肥大型心筋症の治療で使用するためのマバカムテン Pending JP2020529996A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023014110A JP2023065372A (ja) 2017-08-04 2023-02-01 肥大型心筋症の治療で使用するためのマバカムテン
JP2024192836A JP2025020292A (ja) 2017-08-04 2024-11-01 肥大型心筋症の治療で使用するためのマバカムテン

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201762541591P 2017-08-04 2017-08-04
US62/541,591 2017-08-04
US201762584537P 2017-11-10 2017-11-10
US62/584,537 2017-11-10
US201862639922P 2018-03-07 2018-03-07
US62/639,922 2018-03-07
US201862671585P 2018-05-15 2018-05-15
US62/671,585 2018-05-15
PCT/US2018/045180 WO2019028360A1 (en) 2017-08-04 2018-08-03 MAVACAMTEN FOR USE IN THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023014110A Division JP2023065372A (ja) 2017-08-04 2023-02-01 肥大型心筋症の治療で使用するためのマバカムテン

Publications (2)

Publication Number Publication Date
JP2020529996A true JP2020529996A (ja) 2020-10-15
JP2020529996A5 JP2020529996A5 (enExample) 2021-10-07

Family

ID=63350605

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020505487A Pending JP2020529996A (ja) 2017-08-04 2018-08-03 肥大型心筋症の治療で使用するためのマバカムテン
JP2023014110A Pending JP2023065372A (ja) 2017-08-04 2023-02-01 肥大型心筋症の治療で使用するためのマバカムテン
JP2024192836A Pending JP2025020292A (ja) 2017-08-04 2024-11-01 肥大型心筋症の治療で使用するためのマバカムテン

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023014110A Pending JP2023065372A (ja) 2017-08-04 2023-02-01 肥大型心筋症の治療で使用するためのマバカムテン
JP2024192836A Pending JP2025020292A (ja) 2017-08-04 2024-11-01 肥大型心筋症の治療で使用するためのマバカムテン

Country Status (17)

Country Link
US (5) US20200054636A1 (enExample)
EP (2) EP3661514B1 (enExample)
JP (3) JP2020529996A (enExample)
KR (2) KR20200035973A (enExample)
CN (2) CN118593507A (enExample)
AU (2) AU2018311974B2 (enExample)
CA (1) CA3071948A1 (enExample)
IL (2) IL322175A (enExample)
LT (1) LT3661514T (enExample)
MA (1) MA49760A (enExample)
MX (3) MX2020001406A (enExample)
MY (1) MY208231A (enExample)
RU (1) RU2020109345A (enExample)
SG (2) SG11202000549TA (enExample)
SM (1) SMT202500413T1 (enExample)
UY (1) UY37834A (enExample)
WO (1) WO2019028360A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3740481B9 (en) 2018-01-19 2024-10-23 Cytokinetics, Inc. Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
EP3814342B1 (en) 2018-06-26 2022-07-27 Cytokinetics, Inc. Cardiac sarcomere inhibitors
EP3814343B1 (en) 2018-06-26 2023-01-11 Cytokinetics, Inc. Cardiac sarcomere inhibitors
WO2020257609A1 (en) * 2019-06-21 2020-12-24 MyoKardia, Inc. Diagnostics and treatments for cardiac disease
CN110698415B (zh) * 2019-10-21 2023-05-09 上海先行医药开发有限公司 一种肌球蛋白抑制剂及其制备方法和用途
US20230158027A1 (en) * 2019-11-10 2023-05-25 MyoKardia, Inc. Methods of treatment with myosin modulator
WO2021154904A1 (en) * 2020-01-28 2021-08-05 Teva Pharmaceuticals International Gmbh Solid state forms of mavacamten and process for preparation thereof
EP4203927A4 (en) * 2020-08-28 2024-09-04 MyoKardia, Inc. METHODS OF TREATMENT BY MYOSIN MODULATOR
WO2022105852A1 (zh) 2020-11-20 2022-05-27 江苏恒瑞医药股份有限公司 三嗪二酮类衍生物、其制备方法及其在医药上的应用
CA3206864A1 (en) * 2021-02-01 2022-08-04 Divya Jyothi Kallem Process for preparation of mavacamten and solid state forms thereof
MX2023010125A (es) 2021-03-04 2023-09-11 Cytokinetics Inc Inhibidores del sarcomero cardiaco.
CN112939876A (zh) * 2021-03-10 2021-06-11 杭州科巢生物科技有限公司 Mavacamten的晶型I及其制备方法
WO2022189599A1 (en) 2021-03-12 2022-09-15 Sandoz Ag Crystalline forms of mavacamten for the treatment of hcm
RS66640B1 (sr) * 2021-07-16 2025-04-30 Cytokinetics Inc Režimi doziranja aficamtena za lečenje opstruktivne hipertrofične kardiomiopatije
WO2023046413A1 (en) * 2021-09-24 2023-03-30 Koninklijke Philips N.V. Methods and systems for generating likelihood of heart failure with preserved ejection fraction (hfpef)
WO2024097284A1 (en) * 2022-11-02 2024-05-10 MyoKardia, Inc. Mavacamten and derivatives thereof for use in treating atrial dysfunction
AU2024248193A1 (en) 2023-03-27 2025-10-09 Edgewise Therapeutics, Inc. Quinolinone amide compounds and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016522263A (ja) * 2013-06-21 2016-07-28 マイオカーディア，インク 心臓状態に対するピリミジンジオン化合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016522263A (ja) * 2013-06-21 2016-07-28 マイオカーディア，インク 心臓状態に対するピリミジンジオン化合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"History of Changes for Study: NCT02842242", CLINICALTRIALS.GOV ARCHIVE [ONLINE], JPN6022031455, July 2017 (2017-07-01), ISSN: 0005021848 *

Also Published As

Publication number Publication date
MX2024000348A (es) 2024-01-26
MX2020001406A (es) 2020-03-09
CN111182901A (zh) 2020-05-19
KR20250116181A (ko) 2025-07-31
IL272300B1 (en) 2025-08-01
US20250213565A1 (en) 2025-07-03
AU2024203872A1 (en) 2024-06-27
UY37834A (es) 2019-02-28
EP3661514B1 (en) 2025-09-17
IL322175A (en) 2025-09-01
EP3661514A1 (en) 2020-06-10
US20240423981A1 (en) 2024-12-26
JP2025020292A (ja) 2025-02-12
EP4659806A2 (en) 2025-12-10
RU2020109345A (ru) 2021-09-06
MX2024008096A (es) 2024-07-15
CN118593507A (zh) 2024-09-06
CA3071948A1 (en) 2019-02-07
IL272300A (en) 2020-03-31
AU2018311974B2 (en) 2024-03-07
KR20200035973A (ko) 2020-04-06
TW201916882A (zh) 2019-05-01
IL272300B2 (en) 2025-12-01
MY208231A (en) 2025-04-25
SMT202500413T1 (it) 2025-11-10
AU2018311974A1 (en) 2020-02-06
US20200054636A1 (en) 2020-02-20
US20220313695A1 (en) 2022-10-06
WO2019028360A1 (en) 2019-02-07
SG10202112960QA (en) 2021-12-30
US20220226324A1 (en) 2022-07-21
LT3661514T (lt) 2025-11-10
SG11202000549TA (en) 2020-02-27
MA49760A (fr) 2020-06-10
JP2023065372A (ja) 2023-05-12

Similar Documents

Publication Publication Date Title
US20250213565A1 (en) Treatment of hcm with pyrimidinedione compounds
EP4370116B1 (en) Aficamten dosage regimens for treating obstructive hypertrophic cardiomyopathy
CA3190060A1 (en) Methods of treatment with myosin modulator
TW201002676A (en) Use of dronedarone for the preparation of a medicament for use in the prevention of permanent atrial fibrillation
US20240091203A1 (en) Methods for treating non-obstructive hypertrophic cardiomyopathy
JP2022009066A (ja) Ｓ－エコールを用いてアルツハイマー病を診断するおよび治療する方法
JP2019077726A (ja) ウデナフィル組成物を用いてフォンタン患者における心筋性能を改善する方法
Preston et al. Using sotatercept in the care of patients with pulmonary arterial hypertension
JP7620758B2 (ja) 肺動脈性肺高血圧症の治療方法
Lüsebrink et al. How exercise can deteriorate the clinical course of an ARVC patient: a case report
HK40028703A (zh) 用於在肥厚型心肌病的治疗中使用的玛伐凯泰
US20250295639A1 (en) Methods for treating heart diseases
WO2018119190A1 (en) Microtubule polymerization modulators for treating lmna-related dilated cardiomyopathy
El-Damaty et al. Safety of out-of-hospital initiation of flecainide in patients with atrial and ventricular arrhythmias and structurally normal heart
Krishnan et al. A Lifetime in the Making
Marchesini et al. Hypertrophic Cardiomyopathy
Singh et al. Results: The results by analysis of varience revealed that wall thicknes opposite the site of infarction decreased from (mean±SD) 12.2±2.0 mm to 10.0±1.8 mm with coenzyme Q10 compared with 12.8±2.2 mm to 13.3+ 2.3
after Acute Converting Enzyme in Patients

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210802

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210802

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210708

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220613

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220802

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220929

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230328